Evaxion soars on cancer vaccine promise

31 October 2023
evaxion-biotech-large

Danish biotech company Evaxion (Nasdaq: EVAX) has announced initial results from a Phase II trial of the first five metastatic melanoma patients treated with EVX-01, a peptide-based personalized cancer vaccine.

Shares in Evaxion jumped up by 18% during Tuesday morning’s trading following the announcement.

This study is a self-sponsored open-label, single-arm, multicenter trial carried out in collaboration with US pharma giant Merck & Co (NYSE: MRK), and together with leading principal investigators and research centers from Italy and Australia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology